The use of nanostructured materials
for targeted and controlled
delivery of bioactive molecules is an attractive alternative to conventional
drug administration protocols, enabling selective targeting of diseased
cells, lower administered dosages, and reduced systemic side effects.
Although a variety of nanocarriers have been investigated in recent
years, electroactive organic polymer nanoparticles present several
exciting advantages. Here we demonstrate that thin films created from
nanoparticles synthesized from violanthrone-79, an n-type semiconducting
organic material, can incorporate and release dexamethasone in vitro in a highly controlled manner. By systematically
altering the nanoparticle formation chemistry, we successfully tailored
the size of the nanoparticles between 30 and 145 nm to control the
initial amount of drug loaded into the organic particles. The biocompatibility
of the different particles was tested using live/dead assays of dorsal
root ganglion neurons isolated and cultured from mice, revealing that
elevated levels of the sodium dodecyl sulfate surfactant used to create
the smaller nanoparticles are cytotoxic; however, cell survival rates
in nanoparticles larger than 45 nm exceed 86% and promote neurite
growth and elongation. By manipulating the electrical stimulus applied
to the electroactive nanoparticle films, we show an accelerated rate
of drug release in comparison to passive release in aqueous media.
Furthermore, pulsing the electrical stimulus was successfully used
to selectively switch the accelerated release rate on and off. By
combining the tuning of drug loading (through tailored nanoparticle
synthesis) and drug release rate (through electrical stimulus protocols),
we demonstrate a highly advanced control of drug delivery dosage in
a biocompatible delivery vehicle. This work highlights the significant
potential of electroactive organic nanoparticles for implantable devices
that can deliver corticosteroids directly to the nervous system for
the treatment of inflammation associated with neurological disorders,
presenting a translatable pathway toward precision nanomedicine approaches
for other drugs and diseases.